News Release

Journal Article Cites HemoVoid™ and AlbuVoid™ Enrichment for LC-MS Proteomic Analysis of Osteogenic and Fibrogenic Blood Composites

MONMOUTH JUNCTION, NJ, April 15, 2021 -- Biotech Support Group reports on a recent research article describing the simplicity and efficiency of two depletion technologies – one for Albumin and one Hemoglobin, to quantify proteome abundance changes upon biphasic calcium phosphate (BCP) ceramics embedded in blood clots. 

The citation is:

Jing, Lun, et al. "PROTEOMIC ANALYSIS IDENTIFIED LBP AND CD14 AS KEY PROTEINS IN BLOOD/BIPHASIC CALCIUM PHOSPHATE MICROPARTICLE INTERACTIONS." Acta Biomaterialia (2021).

Immediately upon implantation, scaffolds for bone repair are exposed to the patient’s blood. Biphasic calcium phosphate (BCP) ceramics are considered as the gold standard in bone reconstruction surgery. Here, in a LC-MS/MS proteomic study, the authors compared the differentially expressed blood proteins (plasma and blood cell proteins) and the deregulated signaling pathways of osteogenic and fibrogenic blood composites. The article describes use of HemoVoid™ for depletion of Hemoglobin prior to LC-MS analysis, “each composite material or 4 blood clots were pooled into 3ml of cooled lysis buffer [HEPES 50mM (pH 7.4); NaCl 150mM; EDTA 20mM (pH 8); CHAPS 1%; DTT 1mM; Protease and Phosphatase inhibitor cocktail]. They were let on ice for 30min with regular vortexings and centrifuged at 4°C, 8000g, 15 min. The supernatants were collected, and hemoglobin depleted using several HemoVoid™ columns (Biotech Support Group). When indicated, albumin was also partially removed using AlbuVoid™ depletion reagent kit (Biotech Support Group) following the manufacturer’s instructions.” From these enrichment steps, the investigators found respectively 80 and 92 proteins differentially expressed between blood clot and BCP 80-200 or BCP 200-500 blood composites. After albumin depletion, analysis of the significant deregulated proteins showed that 27 signaling pathways significantly changed in blood cells stimulated with BCP 80-200 particles compared to blood cells in blood clot, whereas only 6 of these pathways were significantly deregulated with BCP 200-500 particles. These data obtained after low abundance protein enrichment confirmed that the acute phase response protein, as well as LXR and. FXR pathways, were highly modulated in BCP blood composites but, conversely to what was observed without albumin depletion, these 3 pathways were more strongly altered by the BCP 80- 200 particles. Understanding the molecular events following the interactions of the patient’s blood with biomaterials is crucial in the development of bone substitutes at least as effective as bone grafting. The authors conclude that blood/BCP-induced osteogenesis is associated with a higher expression of fibrinogen (FGN) and an upregulation of the Myd88- and NF-κB-dependent TLR4 signaling cascade. They also highlighted the key role of the LBP/CD14 proteins in the TLR4 activation of blood cells by BCP particles. 

“Here is an excellent report demonstrating a very important advantage of the variety of sample prep products that we supply. First, the article shows the productivity of HemoVoid™ - a negative selection strategy, whereby Hemoglobin very selectively passes through the beads without binding. Also, this article justifies looking at alternative sample prep strategies, as their observational biases can be valuable. Here we see after AlbuVoid™, a different set of regulated proteins and pathways between the sample types. This is mostly a different set of proteins and pathways then what was observed without albumin depletion, demonstrating the value of sub-proteome enrichment.”, states Swapan Roy, Ph.D., President and Founder of Biotech Support Group.

For more information on HemoVoid™, visit:

http://www.biotechsupportgroup.com/HemoVoid-Hemoglobin-Depletion-From-Erythrocytes-p/hvk.htm

For more information of all of our Hemoglobin removal products, visit:

https://www.biotechsupportgroup.com/Hemoglobin-Removal-s/312.htm

For more information on AlbuVoid™, visit:

https://www.biotechsupportgroup.com/AlbuVoid-Albumin-Depletion-and-Low-Abundance-p/avk.htm

For more information on all of our Albumin & IgG removal products, visit:

https://www.biotechsupportgroup.com/Albumin-Removal-s/307.htm

About Biotech Support Group LLC

Converging with cultural and technological disruptions forthcoming in healthcare, Biotech Support Group develops methods for cost effective and efficient sample prep essential for these expanding markets. Following a tiered business strategy, the company continues its growth in the consumable research products area supporting the rapidly expanding installation of LC-MS instrument and computational infrastructure. For this market, key products include: AlbuVoid™ and AlbuSorb™ for albumin depletion, Cleanascite™ for lipid adsorption, and HemogloBind™ and HemoVoid™ for hemoglobin removal. From these innovations, the company has acquired knowledgebase and biomarker intellectual property assets that support discoveries of protein markers from blood, with special emphasis on early detection and personalized medical decisions for cancer patients. For more information, go to http://www.biotechsupportgroup.com

For Business Development, Contact:
Matthew Kuruc 732-274-2866, mkuruc@biotechsupportgroup.com